슬롯 머신 규칙 Sees Shift Towards Combination Therapies as Generic Competition Intensifies
Sales of original statin products, widely used for dyslipidemia treatment, declined in January compared to the same period in 2024.
Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis, making them essential for managing dyslipidemia and reducing cardiovascular disease risk. When monotherapy proves insufficient, they are often combined with ezetimibe, another lipid-lowering agent.
In South Korea, currently approved original statins include Viatris’ Lipitor (atorvastatin), JW Pharmaceutical’s 슬롯 머신 규칙 (pitavastatin), AstraZeneca’s Crestor (rosuvastatin), Novartis’ Lescol XL (fluvastatin), HK inno.N’s Mevalotin (pravastatin), and Organon’s Zocor (simvastatin).
According to 슬롯 머신 규칙 research firm Ubist, outpatient prescription sales of these original statins totaled approximately .7 million in January, reflecting a 6% decrease from .1 million in the same period last year. Prescription volume also declined by 5%, dropping from 54.51 million units to 51.85 million.
Viatris’ Lipitor remained the market leader, with .5 million in outpatient prescription sales, an 8% drop from .4 million last year. However, its sales still exceeded the combined total of the second and third best-selling products—슬롯 머신 규칙 and Crestor. 슬롯 머신 규칙 recorded .5 million (-3% YoY), while Crestor reached .8 million (-6% YoY).
Among all products, Lescol XL saw the sharpest decline, with sales plummeting from 3,000 last year to 1,000 this January, marking a 38% drop in prescription volume.
To counter slowing monotherapy growth, Viatris and JW Pharmaceutical have expanded into combination therapies incorporating ezetimibe. Lipitor Plus (atorvastatin + ezetimibe), co-developed by Viatris and Jeil Pharmaceutical, and JW Pharmaceutical’s 슬롯 머신 규칙zet have gained traction.
슬롯 머신 규칙zet’s sales increased from .9 million last year to .9 million this January, while Lipitor Plus grew from .8 million to .5 million in the same period. JW Pharmaceutical has also expanded 슬롯 머신 규칙’s applications beyond dyslipidemia by introducing 슬롯 머신 규칙 V, a combination of pitavastatin and the antihypertensive drug valsartan, which recorded 9,000 in January.
Despite these efforts to drive new revenue, concerns remain over JW Pharmaceutical’s long-term growth. 슬롯 머신 규칙zet’s use patent expires in August, likely inviting generic competition. Companies such as Ahn-Gook Pharmaceutical, Hanlim Pharmaceutical, Boryung, Daewon Pharmaceutical, and Dongkwang Pharmaceutical have already entered the market since 2023, with more expected to follow.
As price reductions due to post-슬롯 머신 규칙 pricing policies and increasing generic competition intensify, the future strategies of original statin manufacturers will be closely monitored as they strive to maintain 슬롯 머신 규칙 presence.